Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantern PharmaLTRN -0.34%33 Net Current Asset Value is $0.29 as of Mar. 2026, which is 83% below its 10-year median of 1.67. GuruFocus rates LTRN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 940 Biotechnology companies, Lantern Pharma ranks worse than 75% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Lantern Pharma's net current asset value per share for the quarter that ended in Mar. 2026 was $0.29.
The historical rank and industry rank for Lantern Pharma's Net Current Asset Value or its related term are showing as below:
LTRN'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.82 Med: 1.67 Max: 10.45
Current: 10.28
During the past 8 years, the highest Price-to-Net-Current-Asset-Value Ratio of Lantern Pharma was 10.45. The lowest was 0.82. And the median was 1.67.
LTRN's Price-to-Net-Current-Asset-Value is ranked worse than 75% of 940
companies
in the Biotechnology industry
Industry Median: 4.765
vs LTRN: 10.28
Lantern Pharma (NAS:LTRN) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Lantern Pharma Net Current Asset Value Related Terms
Lantern Pharma Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Lantern Pharma's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTRN vs PDSB, AURX, TIL: Net Current Asset Value Comparison
For the Biotechnology subindustry, Lantern Pharma's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantern Pharma Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lantern Pharma's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Lantern Pharma's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.29 mean?
Lantern Pharma (LTRN) has a Net Current Asset Value of $0.29 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Lantern Pharma and its competitors. This is 83% below median its historical median of 1.67. Over the past decade, Lantern Pharma's Net Current Asset Value has ranged from 0.82 to 10.45. According to the industry distribution chart, Lantern Pharma ranks #705 out of 940 companies in the Biotechnology industry, placing it in the top 75%.
Is Lantern Pharma's Net Current Asset Value too high?
Lantern Pharma's current Net Current Asset Value of $0.29 is 83% below median its 10-year median of 1.67. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 10.45. The Biotechnology industry median Net Current Asset Value is 4.77. Lantern Pharma's value of $0.29 is 93.9% below this industry median. Based on the distribution chart, Lantern Pharma ranks #705 out of 940 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lantern Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Lantern Pharma's Net Current Asset Value compare to PDSB and AURX?
According to the Biotechnology industry distribution chart, Lantern Pharma ranks #705 out of 940 companies for Net Current Asset Value. This places Lantern Pharma in the lower half of its industry. The industry median Net Current Asset Value is 4.77. Lantern Pharma's value of $0.29 is 93.9% below this benchmark. Historically, Lantern Pharma's own Net Current Asset Value has ranged from 0.82 to 10.45 over the past decade. While the company's 10-year median is 1.67 vs. the industry median of 4.77, Lantern Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.77, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantern Pharma's current Net Current Asset Value of $0.29 is 93.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Lantern Pharma and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantern Pharma's current Net Current Asset Value is $0.29, which is 83% below median its own 10-year median of 1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantern Pharma stock overvalued right now?
Lantern Pharma (LTRN) has a current Net Current Asset Value of $0.29. The current Net Current Asset Value is $0.29, which is 83% below median its 10-year median of 1.67 and 93.9% below the Biotechnology industry median of 4.77. Lantern Pharma's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Lantern Pharma (LTRN), the current Net Current Asset Value is $0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
33GF Score
Get the complete analysis for LTRN
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTRN has been successfully added to your 
